Health
Immunotherapy drug improves survival over standard chemotherapy for lung cancer patients – News-Medical.Net
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), acco…
Reviewed by Emily Henderson, B.Sc.Oct 1 2020
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), according to a new study led by Yale Cancer Center (YCC) researchers.
The findings, from a global randomized phase 3 clinical trial published today in the New England Journal of Medicine, support the U.S. Food and Drug Administration’s approval of the drug for this indication in May.
These are e…
-
General17 hours agoTeen driver on cocaine racing to Perth nightclub before high-speed crash that killed Nick Campo, court hears
-
Noosa News17 hours agoAirbnb owner hit with disturbing email after house trashed by hundreds of teens
-
Noosa News17 hours agoPolice hunt man who assaulted two women working at Pizza Hut in Townsville
-
Noosa News15 hours agoNew self-serve style chip shop, Chip ‘n’ Mix, in Noosa becomes an instant obsession